Get the latest tech news
Biotech firm creates weight loss pill that mimics the effects of gastric bypass surgery | The pill preserves muscle mass while reducing hunger
SYNT-101 offers a novel approach to weight loss by temporarily altering nutrient absorption in the small intestine. Unlike GLP-1 drugs, which are administered via injection and often...
The science behind SYNT-101 is based on research conducted at MIT by gastroenterologist Giovanni Traverso and chemical engineer Robert Langer, who co-founded Syntis Bio with CEO Rahul Dhanda in 2022. Dr. Louis Aronne, an obesity medicine specialist at Weill Cornell Medical College and a clinical adviser to Syntis Bio, emphasized the drug's promise as a first-line treatment. Dr. Vladimir Kushnir, director of bariatric endoscopy at Washington University in St. Louis, praised the early data but cautioned that larger trials are necessary to fully assess the drug's efficacy and safety.
Or read this on r/tech